Iovance Q1 net loss $107.4M, cash $632.7M; BLA submitted for lifileucel

IOVANCE BIOTHERAPEUTICS, INC.

2023-Q1 EPS reported -$0.50

Q1 net loss $107.4M ($0.50 per share) vs loss of $91.6M ($0.58) in Q1 2022.
Cash $632.7M as of Mar 31, 2023, incl $260.1M from ATM facility; expected to fund into H2 2024.
Completed rolling BLA submission for lifileucel in post-anti-PD-1 advanced melanoma in March 2023.
Plans to acquire Proleukin; closing expected Q2 2023.
Commercial launch preparations for lifileucel on track for 2023; iCTC capacity for 2,000+ patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IOVANCE BIOTHERAPEUTICS, INC. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 9, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and an update on recent developments.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-057722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.